Entero Therapeutics, Inc.

ENTO

US33749P4081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 15:49:37 2024-07-17 EDT			5-day change	1st Jan Change
1.03 ^USD	-0.96%		-7.21%	-75.48%

06-20	Entero Therapeutics, Inc. Announces Transition of Jack Syage from Chief Operating Officer to Chief Scientific Officer	CI
05-20	Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index	CI

AzurRx BioPharma, Inc. announced that it has received $3.99975 million in funding

January 05, 2021

On January 6, 2021, AzurRx BioPharma, Inc. closed the transaction.

Latest news about Entero Therapeutics, Inc.

Entero Therapeutics, Inc. Announces Transition of Jack Syage from Chief Operating Officer to Chief Scientific Officer	06-20	CI
Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index	05-19	CI
First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc	05-17	CI
First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index	05-15	CI
First Wave BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
First Wave BioPharma, Inc. announced a financing transaction	05-09	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	03-14	MT
Sector Update: Health Care	03-14	MT
First Wave BioPharma Shares Fall After Acquiring ImmunogenX	03-14	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data	03-14	MT
First Wave Biopharma, Inc. Announces Management Changes	03-14	CI
First Wave BioPharma, Inc. completed the acquisition of ImmunogenX, LLC for $57.9 million.	03-12	CI
Top Premarket Gainers	01-03	MT
Wall St ticks up, S&P 500 near all-time closing high	12-27	RE
Sector Update: Health Care Stocks Gain Late Afternoon	12-27	MT
First Wave BioPharma Investors Exercise Warrants at Reduced Price -- Shares Up	12-27	MT
Wall St wavers as S&P 500 hovers near all-time closing high	12-27	RE
Sector Update: Health Care Stocks Higher Wednesday Afternoon	12-27	MT
Sector Update: Health Care	12-27	MT
Wall Street rises, S&P close to all-time high	12-27	RE
Traders Look Ahead to Flat Day After Post-Christmas Rally	12-27	MT
US Stock Market Futures Sluggish Following Holiday Gains	12-27	MT
Top Midday Gainers	12-27	MT
Top Premarket Gainers	12-27	MT

Chart Entero Therapeutics, Inc.

Duration

Period

More charts

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.04 USD

Average target price

36 USD

Spread / Average Target

+3,361.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENTERO THERAPEUTICS, INC.	-75.48%	2.57M
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research

Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Biotechnology & Medical Research

AzurRx BioPharma, Inc. announced that it has received $3.99975 million in funding

Latest news about Entero Therapeutics, Inc.

Chart Entero Therapeutics, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research